Founded by Kiran Mazumdar-Shaw, India's richest self-made businesswoman, Biocon is India's biotechnology pioneer. Its founder was named as one of Fortune magazine's 50 Most Powerful Women in 2007 and was instrumental in forging India's biotechnology industry. She set up Biocon in 1978 and has developed it into a global biopharmaceutical player with highly developed research and development facilities focusing on cancer and diabetes treatments.
> Quiz India's mother of invention
Biocon has rapidly developed a robust drug pipeline, led by monoclonal antibodies and other molecules at exciting stages in the bio-pharmaceutical value chain.
Over the years, Biocon has evolved from an enzyme-manufacturing company into a fully integrated bio-pharmaceutical enterprise.
Leveraging India’s globally competitive cost base and exceptional scientific people resource, they are advancing their in-house R&D programs, while also providing custom and clinical research services to international pharmaceutical and biotechnology majors through their subsidiary companies, Syngene and Clinigene.
Biocon is India's first biotechnology company, established in 1978.
It is the first Indian firm to receive US funding for proprietary technologies.
Biocon is the first Indian company to be approved by US FDA for the manufacture of lovastatin, a cholesterol-lowering molecule.
Biocon created a huge stock market buzz in March 2004 with its successful IPO. Day 1 closed with a market value of $1.11 billion.
Subsidiary Companies:
Syngene is a custom research organisation offering synthetic chemistry and molecular biology services for early stage drug discovery and development.
Clinigene is a clinical research organisation offering Phase I-IV clinical trials and studies for novel/generic molecules to international pharmaceutical majors.
Biocon Biopharmaceuticals Private Limited (BBPL) is a joint venture with CIMAB to develop and market a range of monoclonal antibodies and cancer vaccines.
No comments:
Post a Comment